- Home
- ITRG vs MNPR Comparison
ITRG vs MNPR Comparison
Compare ITRG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- MNPR
- Stock Information
- Founded
- ITRG 1997
- MNPR 2014
- Country
- ITRG Canada
- MNPR United States
- Employees
- ITRG N/A
- MNPR N/A
- Industry
- ITRG Precious Metals
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- MNPR Health Care
- Exchange
- ITRG Nasdaq
- MNPR Nasdaq
- Market Cap
- ITRG 277.2M
- MNPR 248.8M
- IPO Year
- ITRG N/A
- MNPR 2019
- Fundamental
- Price
- ITRG $1.67
- MNPR $35.86
- Analyst Decision
- ITRG Strong Buy
- MNPR Strong Buy
- Analyst Count
- ITRG 2
- MNPR 7
- Target Price
- ITRG $3.25
- MNPR $62.00
- AVG Volume (30 Days)
- ITRG 977.5K
- MNPR 20.0K
- Earning Date
- ITRG 08-13-2025
- MNPR 08-12-2025
- Dividend Yield
- ITRG N/A
- MNPR N/A
- EPS Growth
- ITRG N/A
- MNPR N/A
- EPS
- ITRG 0.09
- MNPR N/A
- Revenue
- ITRG $148,447,000.00
- MNPR N/A
- Revenue This Year
- ITRG $792.78
- MNPR N/A
- Revenue Next Year
- ITRG N/A
- MNPR N/A
- P/E Ratio
- ITRG $18.05
- MNPR N/A
- Revenue Growth
- ITRG N/A
- MNPR N/A
- 52 Week Low
- ITRG $0.79
- MNPR $2.15
- 52 Week High
- ITRG $1.95
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ITRG 63.88
- MNPR 44.06
- Support Level
- ITRG $1.54
- MNPR $30.51
- Resistance Level
- ITRG $1.76
- MNPR $42.50
- Average True Range (ATR)
- ITRG 0.08
- MNPR 3.29
- MACD
- ITRG 0.02
- MNPR -1.14
- Stochastic Oscillator
- ITRG 86.36
- MNPR 38.02
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.